. 2020 Oct 14;156(12):1–10. doi: 10.1001/jamadermatol.2020.3617

Table 2. Multivariable Responder Analyses at Week 52 (Exploratory Outcomes)^a.

Variable	PSS = 0		PSS = 0/1		DLQI MCID = 4		DLQI = 0/1		EQ-5D-5L MCID = 0.10		Anxiety scale MCID = 1.5		Depression scale MCID = 1.5
Variable	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value	Odds ratio	P value
Intercept	3.60	.03	5.36	.008	0.44	.48	5.60	.003	6226.71	<.001	0.45	.20	0.85	.81
Risankizumab vs ustekinumab	2.69	<.001	3.10	<.001	5.27	<.001	3.89	<.001	1.80	.01	1.25	.25	1.15	.51
Age	0.99	.21	0.99	.40	1.00	.85	0.99	.25	0.98	.03	1.00	.83	0.99	.10
Sex (female vs male)	0.87	.44	0.86	.45	1.47	.26	1.41	.05	1.01	.96	1.13	.50	0.85	.43
Race (White vs non-White)	1.55	.04	1.58	.04	2.70	.02	1.70	.01	0.84	.47	0.64	.05	1.57	.05
BMI^b	0.96	<.001	0.96	.002	1.01	.73	0.96	<.001	0.97	.04	0.98	.08	0.97	.02
Baseline PASI	1.00	.70	1.01	.44	1.01	.64	1.00	.90	1.04	.005	1.02	.08	1.05	<.001
Smoking status
Current vs ex-smoker	0.70	.10	0.97	.89	0.59	.25	1.06	.81	1.44	.16	1.62	.04	1.77	.02
Current vs never smoked	0.86	.44	0.86	.47	0.72	.43	1.18	.41	1.25	.32	1.03	.88	1.06	.76
Psoriasis duration	1.01	.19	1.00	.54	0.99	.72	1.00	.59	0.98	.07	0.99	.36	0.99	.41
Study (UltIMMa-2 vs UltIMMa-1)	0.97	.88	1.14	.46	0.68	.26	0.75	.09	1.01	.96	0.76	.11	0.77	.16
Prior biologic use (0 vs ≥1)	0.83	.30	0.64	.02	0.53	.07	0.75	.10	0.94	.76	1.58	.01	1.03	.87
PRO baseline value	0.93	.003	0.90	<.001	1.16	<.001	0.94	<.001	0	<.001	1.26	<.001	1.25	<.001

Abbreviations: BMI, body mass index; DLQI, Dermatology Life Quality Index; EQ-5D-5L, 5-level EuroQoL-5D; HADS, Hospital Anxiety and Depression Scale; MCID, Minimal Clinically Important Difference; PASI, Psoriasis Area and Severity Index; PRO, patient-reported outcome; PSS, Psoriasis Symptom Scale; TNF, tumor necrosis factor.

^{^a}

Odds ratios, coefficient estimates, and P values were estimated from multivariable logistic regression models controlling for age, sex (female vs male), race (White vs non-White), BMI, baseline PASI score, smoking status (current smoker vs ex-smoker vs never smoked), psoriasis duration since diagnosis, study indicator, prior biologic use (0 vs ≥1), and baseline value.

^{^b}

Calculated as weight in kilograms divided by height in meters squared.

Table 2. Multivariable Responder Analyses at Week 52 (Exploratory Outcomes)a.

Table 2. Multivariable Responder Analyses at Week 52 (Exploratory Outcomes)^a.